Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Enrico M Novelli, MD, MS

Hematology/Oncology

Associate Professor of Medicine

Director, UPMC Adult Sickle Cell Disease Program

Email: novellie@upmc.edu

Phone: 412-624-2591

Contact
Office: 200 Lothrop Street
Biomedical Science Tower E1240
Pittsburgh, PA 15261
 
Phone: 412-624-2591
Fax: 412-648-5980
E-mail: novellie@upmc.edu
Administrative Assistant:
Linda Mazefsky - Benign Hematology
Address: 3708 Fifth Avenue
5th Floor, Suite 503
Pittsburgh, PA 15213
Email: mazefskyl2@upmc.edu
Phone: 412-648-6466
Fax: 412-647-3659
Education and Training
Education
MD Degree - Summa Cum Laude, Universita' degli Studi di Milano, Italy, 1996
POSTDOCTORAL FELLOWSHIP, University of Pittsburgh, 2001
POSTDOCTORAL FELLOWSHIP, Johns Hopkins University, 1999
Training
INTERNSHIP IN INTERNAL MEDICINE, University of Pittsburgh Medical Center Shadyside, 2004
RESIDENCY IN INTERNAL MEDICINE, University of Pittsburgh Medical Center Shadyside, 2002
FELLOWSHIP IN HEMATOLOGY/ONCOLOGY, UPMC, 2008
Research Interest
Dr. Novelli’s research has focused on the mechanisms underlying vascular dysfunction in SCD via three main projects: 1) Dr. Novelli has explored the role of the protein thrombospondin-1 in SCD. He has found that elevated plasma levels of TSP1 in several large cohorts of patients with SCD are associated with vaso-occlusive complications and identify a subset of patients who display hemostatic activation and have a more severe phenotype. In translational studies presented as podium talk at the American Society of Hematology Annual Meeting he also found TSP1 to cause pulmonary hypertension in transgenic mice by binding to its receptor CD47. 2) Another line of research has focused on the characterization of arterial stiffness as a mechanism of vascular dysfunction in SCD. Dr. Novelli has discovered a new link between hemolysis and arterial stiffness by showing that hemolysis is independently associated with arterial stiffness measured by pulse pressure in a large cohort of SCD patients. This discovery is of high clinical relevance as it suggests that elevated hemolysis rates encountered in a subset of SCD patients may lead to an increased risk of vascular complications; 3) Most recently, Dr. Novelli has turned his attention onto the cerebral vasculature in SCD in an effort to elucidate SCD-related cognitive impairment. He has discovered a neuroimaging marker of small vessel disease associated with cognitive function in SCD.
Clinical Interest
Dr. Novelli's main areas of interest are sickle cell disease and disorders of hemostasis. Dr. Novelli holds a sickle cell disease and hemoglobinopathy clinic at the Hillman Cancer Center and a hemophilia and thrombosis clinic at the Hemophilia Center of Western Pennsylvania. In addition, he works as a member of the inpatient hematology consult service for several weeks of the year. Another longstanding interest of Dr. Novelli’s is in developing global health research and training initiatives in Tropical Hematology
Educational Interest
Because of his commitment to teaching, Dr. Novelli received a secondary appointment as Faculty in the Clinical and Translational Science Institute in 2015 and has been a longstanding Faculty of the Global Health Track of the UPMC Internal Medicine Residency Program
Publications
For my complete bibliography, Click Here.
Selected Publications:
Novelli EM, Sarles CE, Aizenstein HJ, Ibrahim TS, Butters MA, Ritter AC, Erickson KI, Rosano C. Brain Venular Pattern by 7T MRI Correlates with Memory and Hemoglobin in Sickle Cell Anemia. Psychology Research: Psychiatry Research. 2015; 233(1): 18-22.
Novelli EM, Hildesheim M, Rasano C, Vanderpool R, Simon M, Kato GJ, Gladwin MT, MD. Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease. PLoS One. 2014; 9: 12.
George MP, Novelli EM, Shigemura N, Simon MA, Feingold B, Drishnamurti L, Morrell MR, Gries CG, Haider S, Johnson BA, Crespo MM, Bhama JK, Yousem SA, Toyoda Y, Campion HC, Pilewski JP, Bermudex C, Gladwin MT. First successful lung transplantationfor sickle cell disease with severe pulmonary arterial hypertension and pulmonary veno-occlusive disease. Pulmonary Circulation. 2013; 4: 952-8.
Cheng L, Yang Y, Leung W, Ramirez M, Tanavde V, Enger C, Civin CI. Ex-vivo culture of cord blood CD34+ cells expands progenitor cell numbers, preserves engraftment capacity in NOD/SCID mice, and enhances retroviral transduction efficiency. Human Gene Therapy. 1999; 10(18): 2927-40.
Novelli EM, Ramirez M, Leung W, Civin CI. Human hematopoietic stem/progenitor cells generate CD5+ B Lymphoid cells in NOD/SCID mice. Stem Cells. 1999; 17(5): 242-52.
Novelli EM, Huynh C, Gladwin MT, Moore CG`, Ragni MV. Pulmonary Embolism in Sickle Cell Disease: A Case-Control Study. Journal of Thrombosis Haemostasis. 2012; 10(5): 760-6.
Novelli EM, Kato GJ, Hildesheim ME, Barge S, Meyer MP, Lozier J, Hassett AC, Ragni MV, Isenberg JS, Gladwin MT. Thrombospondin-1 Inhibits ADAMTS13 Activity in Sickle Cell Disease. Haematologica. 2013; 11: 132-4.
Sponsored Research/Activities
Title: Multidisciplinary Research Training in Hematology
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: T32 HL149648
Start Year: 2020
End Year: 2025
Title: Multidisciplinary Research Training in Hematology
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: T32 HL149648
Start Year: 2020
End Year: 2021
Title: PET Imaging of Vaso-Occlusion in Sickle Cell Disease: From Mice to Humans
Role: Principal Investigator
Funding Agency: Pittsburgh Foundation
Start Year: 2018
End Year: 2020
Title: PET Imaging of Vaso-Occlusion in Sickle Cell Disease: From Mice to Humans
Role: Principal Investigator
Funding Agency: Pittsburgh Foundation
Grant Number: RES
Start Year: 2018
End Year: 2020
Title: Neuro-Vascular Determinants of Cognition in Adults with Sickle Cell Disease
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL127107
Start Year: 2016
End Year: 2021
Title: Neuro-Vascular Determinants of Cognition in Adults with Sickle Cell Disease
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL127107
Start Year: 2016
End Year: 2021
Title: Pittsburgh Intensive Training in Hematology Research (PITHR)
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R25 HL128640
Start Year: 2015
End Year: 2021
Title: Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest Syndrome
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL128297
Start Year: 2021
End Year: 2025
Title: Progressive degenerative role of Nox and thrombospondin-1 in the aging
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL142248
Start Year: 2019
End Year: 2024
Title: Progressive degenerative role of Nox and thrombospondin-1 in the aging
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL142248
Start Year: 2019
End Year: 2023
Title: A STUDY TO GENERATE SIDE-BY-SIDE VIDEOS OF RBC FLOW/ADHENSION PLUS AND MINUS TREATMENT WITH VOXELOTOR
Role: Co-Investigator
Funding Agency: Massachusetts Institute of Technology / Global Blood Therapeutics
Grant Number: RES
Start Year: 2019
End Year: 2021
Title: 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: UH3 HL143192
Start Year: 2019
End Year: 2020
Title: 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: UH3 HL143192
Start Year: 2019
End Year: 2020
Title: Hemolysis-Induced Platelet mitoROS Drives TSP1 Release and PH Pathogenesis
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL133003
Start Year: 2017
End Year: 2021
Title: Hemolysis-Induced Platelet mitoROS Drives TSP1 Release and PH Pathogenesis
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL133003
Start Year: 2017
End Year: 2021
Title: University of Pittsburgh Clinical and Translational Science Institute (Novelli-Oyin)
Role: Co-Investigator
Funding Agency: National Center for Advancing Translational Sciences
Grant Number: UL1 TR001857
Start Year: 2016
End Year: 2021
Title: Hemostasis and Vascular Biology Research Institute-Novelli
Role: Co-Investigator
Funding Agency: Institute for Transfusion Medicine
Grant Number: H&VBRI
Start Year: 2008
End Year: 2028
Title: Hemostasis and Vascular Biology Research Institute-Novelli
Role: Co-Investigator
Funding Agency: Vitalant Research Institute
Grant Number: RES H&VBRI
Start Year: 2008
End Year: 2028